Dronedarone therapy in atrial fibrillation

A summary of recent controlled trials

G. Duray, Jörn Schmitt, Stefan H. Hohnloser

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Dronedarone is a new multichannel blocker, structurally related to amiodarone but free of iodine and less lipophilic and so expected to be free of iodine-related organ toxicity and tissue accumulation. The drug was developed for the treatment of atrial fibrillation (AF). The phase II Dronedarone Atrial FibrillatioN study after Electrical cardioversion (DAFNE) study established 400 mg twice-daily dosing (bid) as the standard dose for dronedarone in the maintenance of sinus rhythm. In the pivotal phase III European Trial In Atrial Fibrillation Or Flutter Patients Receiving Dronedarone For The Maintenance of Sinus Rhythm/ American-Australian-African Trial With Dronedarone In Atrial Fibrillation/flutter Patients For The Maintenance of Sinus Rhythm (EURIDIS/ADONIS) studies in patients with paroxysmal/persistent AF and atrial flutter, dronedarone significantly prolonged the mean time to first AF/flutter recurrence. Although dronedarone proved to be safe in these AF studies, a trial in patients with severe congestive heart failure was prematurely stopped because of excess mortality in the dronedarone relative to the control group. This finding prompted the conduct of a large randomized study in more than 4600 patients with nonpermanent AF, which used the primary end point of time to first cardiovascular (CV) hospitalization or death. Dronedarone significantly reduced the incidence of the primary as well as several secondary end points among which CV mortality was the most significant one. The results of this development program led to the approval of dronedarone for use in patients with AF in several jurisdictions. This article provides a short summary of the most important findings during the clinical development of dronedarone.

Original languageEnglish
JournalJournal of Cardiovascular Pharmacology and Therapeutics
Volume15
Issue number4 SUPPL.
DOIs
Publication statusPublished - Dec 2010

Fingerprint

Atrial Fibrillation
Atrial Flutter
Therapeutics
Maintenance
Iodine
dronedarone
Electric Countershock
Amiodarone
Mortality
African Americans
Hospitalization
Heart Failure
Recurrence
Control Groups
Incidence

Keywords

  • antiarrhythmic drugs
  • atrial fibrillation
  • dronedarone
  • hospitalization
  • mortality

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Cardiology and Cardiovascular Medicine

Cite this

Dronedarone therapy in atrial fibrillation : A summary of recent controlled trials. / Duray, G.; Schmitt, Jörn; Hohnloser, Stefan H.

In: Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 15, No. 4 SUPPL., 12.2010.

Research output: Contribution to journalArticle

@article{c38ead37f1c04190a3a582f3a5c77aab,
title = "Dronedarone therapy in atrial fibrillation: A summary of recent controlled trials",
abstract = "Dronedarone is a new multichannel blocker, structurally related to amiodarone but free of iodine and less lipophilic and so expected to be free of iodine-related organ toxicity and tissue accumulation. The drug was developed for the treatment of atrial fibrillation (AF). The phase II Dronedarone Atrial FibrillatioN study after Electrical cardioversion (DAFNE) study established 400 mg twice-daily dosing (bid) as the standard dose for dronedarone in the maintenance of sinus rhythm. In the pivotal phase III European Trial In Atrial Fibrillation Or Flutter Patients Receiving Dronedarone For The Maintenance of Sinus Rhythm/ American-Australian-African Trial With Dronedarone In Atrial Fibrillation/flutter Patients For The Maintenance of Sinus Rhythm (EURIDIS/ADONIS) studies in patients with paroxysmal/persistent AF and atrial flutter, dronedarone significantly prolonged the mean time to first AF/flutter recurrence. Although dronedarone proved to be safe in these AF studies, a trial in patients with severe congestive heart failure was prematurely stopped because of excess mortality in the dronedarone relative to the control group. This finding prompted the conduct of a large randomized study in more than 4600 patients with nonpermanent AF, which used the primary end point of time to first cardiovascular (CV) hospitalization or death. Dronedarone significantly reduced the incidence of the primary as well as several secondary end points among which CV mortality was the most significant one. The results of this development program led to the approval of dronedarone for use in patients with AF in several jurisdictions. This article provides a short summary of the most important findings during the clinical development of dronedarone.",
keywords = "antiarrhythmic drugs, atrial fibrillation, dronedarone, hospitalization, mortality",
author = "G. Duray and J{\"o}rn Schmitt and Hohnloser, {Stefan H.}",
year = "2010",
month = "12",
doi = "10.1177/1074248410368530",
language = "English",
volume = "15",
journal = "Journal of Cardiovascular Pharmacology and Therapeutics",
issn = "1074-2484",
publisher = "SAGE Publications Ltd",
number = "4 SUPPL.",

}

TY - JOUR

T1 - Dronedarone therapy in atrial fibrillation

T2 - A summary of recent controlled trials

AU - Duray, G.

AU - Schmitt, Jörn

AU - Hohnloser, Stefan H.

PY - 2010/12

Y1 - 2010/12

N2 - Dronedarone is a new multichannel blocker, structurally related to amiodarone but free of iodine and less lipophilic and so expected to be free of iodine-related organ toxicity and tissue accumulation. The drug was developed for the treatment of atrial fibrillation (AF). The phase II Dronedarone Atrial FibrillatioN study after Electrical cardioversion (DAFNE) study established 400 mg twice-daily dosing (bid) as the standard dose for dronedarone in the maintenance of sinus rhythm. In the pivotal phase III European Trial In Atrial Fibrillation Or Flutter Patients Receiving Dronedarone For The Maintenance of Sinus Rhythm/ American-Australian-African Trial With Dronedarone In Atrial Fibrillation/flutter Patients For The Maintenance of Sinus Rhythm (EURIDIS/ADONIS) studies in patients with paroxysmal/persistent AF and atrial flutter, dronedarone significantly prolonged the mean time to first AF/flutter recurrence. Although dronedarone proved to be safe in these AF studies, a trial in patients with severe congestive heart failure was prematurely stopped because of excess mortality in the dronedarone relative to the control group. This finding prompted the conduct of a large randomized study in more than 4600 patients with nonpermanent AF, which used the primary end point of time to first cardiovascular (CV) hospitalization or death. Dronedarone significantly reduced the incidence of the primary as well as several secondary end points among which CV mortality was the most significant one. The results of this development program led to the approval of dronedarone for use in patients with AF in several jurisdictions. This article provides a short summary of the most important findings during the clinical development of dronedarone.

AB - Dronedarone is a new multichannel blocker, structurally related to amiodarone but free of iodine and less lipophilic and so expected to be free of iodine-related organ toxicity and tissue accumulation. The drug was developed for the treatment of atrial fibrillation (AF). The phase II Dronedarone Atrial FibrillatioN study after Electrical cardioversion (DAFNE) study established 400 mg twice-daily dosing (bid) as the standard dose for dronedarone in the maintenance of sinus rhythm. In the pivotal phase III European Trial In Atrial Fibrillation Or Flutter Patients Receiving Dronedarone For The Maintenance of Sinus Rhythm/ American-Australian-African Trial With Dronedarone In Atrial Fibrillation/flutter Patients For The Maintenance of Sinus Rhythm (EURIDIS/ADONIS) studies in patients with paroxysmal/persistent AF and atrial flutter, dronedarone significantly prolonged the mean time to first AF/flutter recurrence. Although dronedarone proved to be safe in these AF studies, a trial in patients with severe congestive heart failure was prematurely stopped because of excess mortality in the dronedarone relative to the control group. This finding prompted the conduct of a large randomized study in more than 4600 patients with nonpermanent AF, which used the primary end point of time to first cardiovascular (CV) hospitalization or death. Dronedarone significantly reduced the incidence of the primary as well as several secondary end points among which CV mortality was the most significant one. The results of this development program led to the approval of dronedarone for use in patients with AF in several jurisdictions. This article provides a short summary of the most important findings during the clinical development of dronedarone.

KW - antiarrhythmic drugs

KW - atrial fibrillation

KW - dronedarone

KW - hospitalization

KW - mortality

UR - http://www.scopus.com/inward/record.url?scp=78649834234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649834234&partnerID=8YFLogxK

U2 - 10.1177/1074248410368530

DO - 10.1177/1074248410368530

M3 - Article

VL - 15

JO - Journal of Cardiovascular Pharmacology and Therapeutics

JF - Journal of Cardiovascular Pharmacology and Therapeutics

SN - 1074-2484

IS - 4 SUPPL.

ER -